LifeScan launches Global Diabetes Handprint campaign
MILPITAS, Calif. LifeScan, the maker of OneTouch Brand Blood Glucose Monitoring Systems for people with diabetes, on Monday launched its Global Diabetes Handprint (www.DiabetesHandprint.com) initiative, developed in collaboration with the Diabetes Hands Foundation.
The Global Diabetes Handprint is inviting people with diabetes to submit images of their hand, decorated with words and graphics depicting their personal expressions about living with diabetes. The images will in turn be showcased on the Diabetes Handprint Web site, encouraging visitors to share their own hand images.
“The idea behind the original ‘Word In Your Hand’ project was to inspire people with diabetes to connect with one another and not feel so isolated,” Manny Hernandez, president of the Diabetes Hands Foundation said. “Now, the Global Diabetes Handprint expands this concept by reaching more people than ever before, encouraging them in their daily struggle with diabetes while giving back to the diabetes community with company donations.”
For each image submitted between now and March 31, OneTouch will donate $5 up to a maximum of $250,000 for diabetes charities.
The funds generated by participation in the Global Diabetes Handprint will be donated to the Diabetes Education and Camping Association to support children’s diabetes camps and to Taking Control of Your Diabetes to support adult educational and motivational conferences for people with diabetes, those at risk and their loved ones.2 Participants will designate which organization—DECA or TCOYD—will receive the donation associated with their image submission.
As the Diabetes Handprint Project progresses, the images posted by site visitors will be combined to create an interactive, hand-shaped mosaic. Visitors to www.DiabetesHandPrint.com will be able to search for individual images or view them by moving their cursor across the mosaic. Additionally, there will be a featured image, which will be updated regularly. OneTouch will also select five individuals and their images by Dec. 31 to later feature in a national promotional campaign for the Global Diabetes Handprint project.
Flavours launches NutraBitz all-natural, probiotic soft chews
CORONA, Calif. Flavours Inc. on Monday announced the introduction of NutraBitz, a line of all-natural, oat-based soft chews containing both prebiotics and probiotics for private label applications.
“Probiotics are one of the hottest market trends today, but right now consumers can’t get them in delivery forms that make taking probiotics enjoyable. NutraBitz changes that,” Flavours Inc. director of sales, Tara Foster, said.
Flavours plans to showcase the new product offering Supply Side West, which is being held Oct. 22-24 in Las Vegas.
According to the company, the idea for NutraBitz was inspired by the continuing emergence of medical research demonstrating the benefits of probiotics in a wide variety of health conditions and growing consumer interest and demand for probiotic alternatives to refrigerated yogurts and probiotic capsules and tablets. “Consumers are now much more aware of the benefits of probiotics and are looking for other ways of getting them into the daily diet,” the company stated.
Each 5.5 gram NutraBitz soft chew is 15-20 calories and contains 1 billion CFU of the GanedenBC30 strain of Bacillus coagulans probiotics.
GlaxoSmithKline and Merix settle extended dispute over advertising practices
CHICAGO According to court documents filed last month, Merix Pharmaceutical and GlaxoSmithKline have settled a three-year dispute over advertising and competition practices for an undisclosed amount. “In exchange for certain consideration, the settlement agreement calls for Merix to dismiss with prejudice its claims against GSK, with each side to bear its own costs, expenses and attorneys’ fees,” the court documents, filed Sept. 2, read.
Merix had filed suit in March 2005 charging that certain advertising claims made by GlaxoSmithKline in support of its cold sore remedies Abreva and Valtrex may be false and misleading, using unreliable test data to promulgate advertising claims in an intentional effort to deceive doctors and the public.